Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 198.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 556.00 | |
500 mg | In stock | $ 1,220.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity. |
Targets&IC50 | REH cells:0.44 μM, OCI-AML3 cells:0.24 μM, MOLM-13:0.33 μM, NALM6:0.32 μM |
In vitro | In both solid and ALL transplant tumor models, oral administration of JNJ-26854165 (20 mg/kg) significantly altered EFS distribution. |
In vivo | In leukemia cell lines, JNJ-26854165 inhibits cell growth and induces apoptosis, demonstrating inhibitory effects on OCI-AML-3 (IC50=0.24 μM), MOLM-13 (IC50=0.33 μM), NALM-6 (IC50=0.32 μM), and REH (IC50=0.44 μM). Additionally, it inhibits cell proliferation in various human cancer cell lines (H460, A549, p53-WT-HCT116, and p53-null-HCT116). |
Cell Research | Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK(Only for Reference) |
Synonyms | JNJ-26854165 |
Molecular Weight | 328.41 |
Formula | C21H20N4 |
CAS No. | 881202-45-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 2 mg/mL (6.08 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 61 mg/mL (185.7 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Serdemetan 881202-45-5 Apoptosis Ubiquitination E1/E2/E3 Enzyme Mdm2 p53 E3 ligating enzyme Ubiquitin activating enzyme E1 activating enzyme Ubiquitin ligase Inhibitor JNJ26854165 E2 conjugating enzyme JNJ 26854165 inhibit JNJ-26854165 Ubiquitin conjugating enzyme MDM-2/p53 inhibitor